Australian Pharmaxis Reports Positive Results From Phase III Bronchitol Cystic Fibrosis Study
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Sydney-based Pharmaxis announced Dec. 2 positive headline results from its second Phase III trial of Bronchitol (mannitol) in people with cystic fibrosis